📰 Keytruda Lenvima News
Keytruda Lenvima News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Keytruda Lenvima. Real-time updates on events, politics, business and more.
May 24, 2024
Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.
August 25, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck squamous c
April 10, 2023
Two clinical trials investigating Keytruda plus Lenvima will be discontinued after the drug duo was not superior to other regimens for melanoma and colorectal cancer subsets.
December 13, 2020
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer Combination treatment topped Pfizers Sutent in phase 3 Merck & Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in advanced renal cell carcinoma (a form of kidney cancer). The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) com...